Insulin inhalation - Coremed

Drug Profile

Insulin inhalation - Coremed

Alternative Names: Alveair

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Coremed
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes mellitus

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Diabetes-mellitus in USA (Inhalation, Aerosol)
  • 24 Jul 2013 Biomarkers information updated
  • 06 Jul 2005 Data presented at the 65th Scientific Sessions of the American Diabetes Association (ADA-2005) have been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top